
AFMDQ
Healthcare · Biotechnology · $1,639 market cap
$0.00010.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2024 | Before the open | -0.95 | -0.94 | +1.1% |
| Sep 5, 2024 | Time not confirmed | -1.02 | -1.01 | +0.8% |
| Jun 12, 2024 | Before the open | -1.58 | -1.27 | +19.6% |
| Mar 28, 2024 | Time not confirmed | -1.61 | -6.52 | -305.0% |
| Nov 14, 2023 | Before the open | -1.85 | -1.60 | +13.5% |
| Aug 10, 2023 | Before the open | -1.81 | -2.00 | -10.5% |
| May 23, 2023 | Before the open | -1.97 | -2.10 | -6.6% |
| Mar 23, 2023 | Time not confirmed | — | -2.33 | — |
| Nov 15, 2022 | Before the open | -1.62 | -1.10 | +32.1% |
| Aug 11, 2022 | Before the open | -1.65 | -1.30 | +21.2% |
| Jun 1, 2022 | Before the open | -1.88 | -1.40 | +25.5% |
| Nov 10, 2021 | Before the open | -1.67 | -1.40 | +16.2% |
| Jul 1, 2021 | Before the open | -1.15 | 0.10 |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent,…
| +108.7% |
| Apr 15, 2021 | Time not confirmed | — | -1.98 | — |
| Nov 10, 2020 | Before the open | -0.83 | -0.70 | +15.7% |
| Aug 11, 2020 | Before the open | -1.43 | -1.60 | -11.9% |
| Jun 23, 2020 | Before the open | -1.28 | -1.10 | +14.1% |
| Nov 19, 2019 | Before the open | -1.97 | -1.70 | +13.7% |
| Aug 7, 2019 | Before the open | -1.43 | -1.70 | -18.9% |
| May 22, 2019 | Before the open | -1.59 | 0.30 | +118.9% |
| Mar 27, 2019 | Time not confirmed | — | 1.60 | — |
| Nov 7, 2018 | Before the open | -1.54 | -1.90 | -23.4% |
| Aug 8, 2018 | Before the open | -1.47 | -1.30 | +11.6% |
| May 15, 2018 | Before the open | -1.50 | -1.50 | 0.0% |
| Mar 20, 2018 | Time not confirmed | — | -1.65 | — |